S-1/A - Cosmos Health Inc. (0001474167) (Filer)

S-1/A - Cosmos Health Inc. (0001474167) (Filer)

S-1/A - Cosmos Health Inc. (0001474167) (Filer)

S-1 - Cosmos Health Inc. (0001474167) (Filer)

424B3 - Cosmos Health Inc. (0001474167) (Filer)

EFFECT - Cosmos Health Inc. (0001474167) (Filer)

S-1/A - Cosmos Health Inc. (0001474167) (Filer)

S-1/A - Cosmos Health Inc. (0001474167) (Filer)

8-K - Cosmos Health Inc. (0001474167) (Filer)

10-Q - Cosmos Health Inc. (0001474167) (Filer)

CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.He is a medical specialist in onc

THESSALONIKI, GREECE / ACCESSWIRE / November 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today provided a business update and reported financial results for the third quarter and nine months ended September 30, 2023.Third Quarter 2023 Financial HighlightsRevenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded

CHICAGO, IL / ACCESSWIRE / August 8, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today the engagement of KPMG Certified Auditors S.A. ("KPMG") as the Company's independent registered public accounting firm, effective August 7, 2023. KPMG replaces the Company's former auditor, Armanino LLP.The appointment of KPMG was made by the Cosmos Health Board of Directors at the recommendation of its Audit Committee. The decision to change auditors was not the result of any disagreement between the Company

CHICAGO, IL / ACCESSWIRE / February 1, 2023 / Cosmos Health Inc. ("the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, is pleased to announce the appointment of Nikos Bardakis, who comes with over two decades of international branded pharmaceutical sector experience, as the Chief Operating Officer (COO).As the Chief Operating Officer at Cosmos Health, Mr. Bardakis' objective will be to bring new capabilities and processes into the organization for optimizing operational excellence towards global commercial expansion of Cosmos' premium products. In addition, M

CHICAGO, IL / ACCESSWIRE / July 22 , 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced that it has appointed finance veteran Dr. Manfred Ziegler to the Company's Advisory Board.Dr. Ziegler brings over 30 years of executive management, financial, and operational experience, as well as extensive expertise in mergers and acquisitions, with a particular focus on high-growth public and private companies. Notably, Dr. Manfred Ziegler served as Chief Executive Officer of CC Pharma, a l

CHICAGO, IL / ACCESSWIRE / May 3, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced it has appointed finance veteran Dr. Anastasios Aslidis to the Board of Directors and as a member of the Board's audit committee.Dr. Anastasios Aslidis currently serves as the Chief Financial Officer and Treasurer, as well as a member of the Board of Directors of EuroDry (EDRY) since 2018. He is Chief Financial Officer, Treasurer and a member of the Board of Directors of Euroseas (NASDAQ:ESEA) si

CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a distribution agreement with Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax") to distribute Virax-branded Avian Influenza Virus ("AIV") Real-Time PCR Kits across various major European markets and certain Gulf Cooperation Council (GCC) countries.Specifically, Cosmos Health gains exclusive rights t

CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.He is a medical specialist in onc

CHICAGO, IL / ACCESSWIRE / December 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, and CFO, George Terzis, increased their stake in the Company by approximately 343,122 common shares, valued at $200,000, based on the closing share price on Friday, December 20, 2024.Specifically, Mr. Siokas increased his stake by approximately 257,334 common shares, valued at $150,000, while Mr.

CHICAGO, IL / ACCESSWIRE / November 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that, on November 25, 2024, Taglich Brothers, Inc. ("Taglich") published an updated research report on the Company's common stock.Key highlights from Taglich's report include:Speculative Buy rating with a $3 price target, suggesting a fourfold increase in the share price over the next 12 months.Significant growth projected,

CHICAGO, IL / ACCESSWIRE / November 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has adopted a strategy to include Bitcoin and Ethereum as part of its treasury reserve assets.The adoption of this new policy follows the Company's forward-thinking approach to investing in new technologies, including the recent acquisition of Cloudscreen, its AI-driven drug repurposing platform.The Company expects

Stable revenue and gross profit despite cost-cutting initiatives, indicating the strength of underlying segments and brands.Solid liquidity position, with cash and cash equivalents exceeding $3.3 million.Hard assets, mainly comprised of debt-free properties, valued at over $12 million; exceeding total debt and providing financing flexibility.Liquid inventory position and accounts receivable that are collected at an accelerated pace provide additional flexibility.Record-breaking results at CosmoFarm and in Amazon UK sales.Various cost-cutting and efficiency initiatives are underway as revenue accelerates, with a focus on high-margin segments like CMO and proprietary brands.CHICAGO, IL / ACCES

CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone

CHICAGO, IL / ACCESSWIRE / November 1, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its healthcare distribution business, operated through its wholly owned subsidiary, CosmoFarm S.A. ("CosmoFarm"), has achieved record sales.In the first ten months of 2024, CosmoFarm achieved record revenue of approximately $43 million, representing an 8.62% increase over the same period last year and contributing to a

CHICAGO, IL / ACCESSWIRE / September 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that sales of its proprietary brands, including Sky Premium Life, on Amazon in the United Kingdom have surged by 160%, increasing to $596,000 year-to-date in 2024 from $230,000 during the same period in 2023.Greg Siokas, CEO of Cosmos Health, stated: "We are delighted that our proprietary brands are being very well receive

CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received its first round of purchase orders in the United Kingdom (UK) for its antimicrobial wash, C-Scrub Wash Chlorhexidine 4% ('C-Scrub'), exceeding $500,000. The orders cover the period from July 2024 to September 2024.Cosmos Health is in the process of securing additional orders for October 2024 and beyond

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

4 - Cosmos Health Inc. (0001474167) (Issuer)

CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone

CHICAGO, IL / ACCESSWIRE / March 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the initiation of the development of Cloudscreen 2.0, the new iteration of its groundbreaking Artificial Intelligence (AI) drug repurposing platform.As previously announced, on January 23, 2024, Cosmos Health completed the acquisition of Cloudscreen. Building on the success of its predecessor, Cloudscreen 2.0 represents a sign

CHICAGO, IL / ACCESSWIRE / January 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has successfully completed the acquisition of Cloudscreen®, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023.Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new tar

CHICAGO, IL / ACCESSWIRE / January 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has successfully completed the acquisition of the licenses and rights of a comprehensive portfolio of 10 generic drugs from a related party for €3.2 million, or approximately $3.5 million at today's exchange rate.This strategic acquisition significantly enhances Cosmos Health's pharmaceutical portfolio. The selected d

CHICAGO, IL / ACCESSWIRE / May 17, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today provided a business update and reported financial results for the first quarter ended March 31, 2023.First Quarter 2023 Financial HighlightsRevenues amounted to $12.35 million, compared to $13.07 million in Q1 2022. When considered on a constant currency basis, using quarterly average Q1 2022 exchange rates, revenues were virtually flat at $13.03 million, highlighting the stability of our platform.Adjusted EBITDA was $0.4

CHICAGO, IL / ACCESSWIRE / May 3, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that is has acquired the entire property which houses the operations of its wholly owned subsidiary CosmoFarm Pharmaceuticals ("CosmoFarm"), a fully licensed pharmaceutical wholesale company operating in the western part of Athens, Greece.The CosmoFarm property, pictured below, comprises an entire 3-story building, 2,700 square meters (or approximately 29,063 square feet) in size. The purchase price was €966,000

CHICAGO, IL / ACCESSWIRE / April 3, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has successfully completed the acquisition of ZipDoctor, Inc. ("ZipDoctor") from American International Holdings Corp (AMIH). The financial terms of the acquisition were not disclosed.ZipDoctor is a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioural health

CHICAGO, IL / ACCESSWIRE / February 2, 2023 / Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that is has begun the application process to dual list its shares on Upstream, the trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ").The planned dual listing on Upstream is designed to provide Cosmos Health the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, increasing liquidity a

First commercial launch of the Company's nutraceutical products in the U.S. follows successful launches on Amazon in other key marketsCHICAGO, IL / ACCESSWIRE / June 2 , 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced that the Company's subsidiary, SkyPharm S.A., a pharmaceutical wholesaler and distributor, is launching Sky Premium Life products on Amazon in the United States. Cosmos expects to introduce fifteen Sky Premium Life SKUs in the third quarter of 2022, and targets h

Reports Positive Net Income of $0.2 Million and $1.2 Million of EBITDA for the First Quarter of 2022CHICAGO, IL / ACCESSWIRE / May 18, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today provided a business update and reported financial results for the first quarter ended March 31, 2022.Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated, "I am pleased to report revenue increased 12.5% to $13.1 million, gross profit increased 88.9% to $1.89 million and we achieved profitability

SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

SC 13G - Cosmos Health Inc. (0001474167) (Subject)

SC 13D/A - Cosmos Health Inc. (0001474167) (Subject)

SC 13D/A - Cosmos Health Inc. (0001474167) (Subject)

SC 13D - Cosmos Holdings Inc. (0001474167) (Subject)

SC 13D/A - Cosmos Holdings Inc. (0001474167) (Subject)

SC 13D - Cosmos Holdings Inc. (0001474167) (Subject)